Filter your results
- 2
- 1
- 3
- 3
- 3
- 3
- 2
- 1
- 1
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse modelsArthritis Research & Therapy, 2022, 24 (1), pp.13. ⟨10.1186/s13075-021-02709-2⟩
Journal articles
hal-03985048v1
|
||
|
Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse modelsArthritis Research and Therapy, 2022, ⟨10.1186/s13075-021-02709-2⟩
Journal articles
hal-03844870v1
|
||
|
IL ‐2‐related regulatory CD4 T‐cell deficiency leads to the development of lung fibrosis and vascular remodelingArthritis & rheumatology, 2022, Online ahead of print. ⟨10.1002/art.42111⟩
Journal articles
inserm-03652770v1
|